SYSTEMATIC REVIEW article
Front. Pediatr.
Sec. Pediatric Pulmonology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1654973
Efficacy and safety of nebulized inhalation versus intramuscular delivery of interferon α1b injection for paediatric patients with viral respiratory diseases: A systematic review and meta-analysis
Provisionally accepted
- 1Department of Orthopedics, Shaanxi Provincial People's Hospital, Xi'an, China
- 2Shaanxi Provincial People's Hospital, Xi'An, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: To systematically evaluate the efficacy and safety of nebulized inhalation versus intramuscular delivery of interferon α1b (IFN α1b) for paediatric patients with viral respiratory diseases. Methods: A comprehensive search of databases including PubMed, Web of Science, Cochrane, Embase, China National Knowledge Infrastructure (CNKI), and China Biology Medicine disc (Sinomed) was conducted to identify relevant literature on the use of interferon α1b in children. The search timeframe spanned from database inception to April 2025. Results: A total of 16 studies involving 2002 patients were included. The meta-analysis revealed that the overall efficacy rate in the nebulized inhalation group (94.85%) was significantly greater than that in the intramuscular injection group (82.39%) (P < 0.00001). Consistent results were observed in the herpangina and bronchiolitis subgroup analyses (P < 0.0001). With respect to drug safety, the meta-analysis results revealed that the incidence rate of adverse reactions in the nebulized inhalation group (1.58%) was significantly lower than that in the intramuscular injection group (4.60%) (P = 0.003). The studies had no significant publication bias, and sensitivity analysis suggested that the results were reliable. Conclusion: Compared with intramuscular injection, nebulized inhalation significantly increased the efficacy and safety of IFN α1b in treating paediatric patients with viral respiratory diseases. For children with both herpangina and bronchiolitis, nebulized inhalation was more effective; however, no significant difference was found in the incidence of adverse reactions. In the future, multicentre, large-scale randomized controlled trials should be conducted to further validate these conclusions.
Keywords: Interferon α1b, nebulized inhalation therapy, paediatric viral respiratory diseases, efficacy, Safety
Received: 07 Jul 2025; Accepted: 06 Oct 2025.
Copyright: © 2025 Yang, Cao, Zhu, Zhao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Peng Zhang, 853291834@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.